Compare iShares MSCI Indonesia ETF (EIDO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | INO | |
|---|---|---|
52-Week High | $19.22 | $2.87 |
52-Week Low | $10.80 | $0.66 |
Market Cap | — | $78.55M |
Sector | — | Health |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.69, down 0.47% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces resistance near $13 and support at $12. Recent news highlights Indonesia's economic initiatives and central bank rate hikes, but the ETF's heavy financials weighting and weak price action persist. Key financial ratios are not provided in the current dataset.
The outlook remains cautious due to technical downtrend and external pressures on Asian equities. Opportunities exist if Indonesia's AI integration and reforestation plans boost economic growth, but risks include currency volatility and limited earnings growth. Investor sentiment is neutral to bearish amid capital outflows from regional markets.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
